Among a plethora of novel immunotherapeutic and targeted agents, the treatment landscapes for small cell lung cancer and non鈥搒mall cell lung cancer have witnessed a rapid expansion that has led to improved survival and quality of life for patients, including a wider range of patients who harbor molecular abnormalities. In an interview with OncLive庐 during an Institutional Perspectives in Cancer virtual webinar on lung cancer, Jared Weiss, MD, associate professor of medicine in oncology, discussed the evolving paradigm for patients with SCLC amid novel therapeutic advances, the importance of NGS in NSCLC, and additions to the targeted therapy armamentarium for a growing number of actionable alterations in NSCLC.